Phase 1 study shows promising results for off-the-shelf trispecific antibody for myeloma
An ongoing phase 1 study observed an 86% overall response rate (ORR) in patients with multiple myeloma (MM) treated with the novel trispecific
Multiple Myeloma News
SOHO 2025
Meetings / Conferences
News
Multiple Myeloma News
SOHO 2025
Meetings / Conferences
Addition of lisaftoclax to myeloma regimens improved depth of response
A phase 1b/2 study added the investigational BCL-2 inhibitor lisaftoclax to pomalidomide/dexamethasone (Pd) and daratumumab/lenalidomide/dexamethasone (DRd) regimens and observed improved outcomes in patients
Multiple Myeloma News
SOHO 2025
Meetings / Conferences
Daratumumab, bortezomib, lenalidomide, dexamethasone combo shows efficacy in myeloma across risk groups
A study presented by Saad Usmani, MD, MBA, of the Memorial Sloan Kettering Cancer Center, as part of the SOHO 2025 Annual Meeting,
Multiple Myeloma News
SOHO 2025
Meetings / Conferences
Addition of mezigdomide to myeloma treatment regimens shows promise for relapsed/refractory disease
Results from the phase 1/2 CA057-003 study showed early efficacy and safety with the addition of mezigdomide to novel combinations for relapsed or
Multiple Myeloma News
SOHO 2025
Meetings / Conferences
Elranatamb, daratumumab, lenalidomide combo induces early responses in newly diagnosed MM
The phase 3 MagnetisMM-6 study showed a manageable safety profile and high response rates in transplant-ineligible, newly diagnosed multiple myeloma (MM) patients treated
Multiple Myeloma News
SOHO 2025
News
Belantamab mafodotin, pomalidomide, dexamethasone combo a “potential standard of care” for relapsed/refractory MM
Ongoing results from the DREAMM-8 trial reinforced the clinically meaningful progression-free survival (PFS) benefit of belantamab mafodotin, pomalidomide, and dexamethasone (BPd) versus pomalidomide,
Multiple Myeloma News
SOHO 2025
News
Phase 3 CEPHEUS study shows “strong efficacy” of quadruplet therapy for transplant-ineligible myeloma
The addition of daratumumab to bortezomib, lenalidomide, and dexamethasone (D-VRd) improved outcomes in patients with newly diagnosed multiple myeloma (MM) compared with VRd
Multiple Myeloma News
SOHO 2025
Meetings / Conferences
Phase 3 study shows benefits of early intervention with daratumumab monotherapy for high-risk SMM
A study presented by Meletios Dimopoulos, MD, of the National and Kapodistrian University of Athens, as part of the SOHO 2025 Annual Meeting,
Multiple Myeloma News
SOHO 2025
Meetings / Conferences
News
Triplet combo shows promise in early-phase trial for newly diagnosed MM
A phase 1/2 study showed that iberdomide, daratumumab, and dexamethasone (IBERDd) had a manageable safety profile when used in transplant-ineligible, newly diagnosed multiple
Lymphoma
Indolent B-Cell Lymphomas
Poor outcomes in a subgroup of follicular lymphoma prompts need for personalized treatment approach
Prior studies have shown conflicting outcomes for patients with different follicular lymphoma (FL) grade subtypes. A recent study by Patrizia Mondello, MD, PhD